Feminai

Cover Block

Name	Feminai
Tagline	Wearable, disposable self-exam patch and AI software for remote breast-cancer screening.
Headquarters	Tel Aviv, Israel
Founded	2023 [Preqin]
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$10,000,000) [Feminai, 2026]

Links

• Website: https://www.feminai.com/
• LinkedIn: https://il.linkedin.com/company/feminai

Executive Summary

Feminai is a healthtech startup attempting to shift breast cancer screening from the clinic to the home. Founded in 2023, the company is developing a wearable, disposable patch paired with AI software designed to analyze tissue changes and deliver a remote assessment [Preqin]. The reported clinical performance, with 96% sensitivity and 98% negative predictive value from trials at Sheba Medical Center, provides an initial technical signal [Clinical Breast Cancer, 2026].

The founding team is led by Karny Ilan, MD, a former general surgery resident, supported by co-founders in CTO and CPO roles [The Jerusalem Post, 2026]. The company has raised $10 million in total capital, anchored by a $6 million seed round led by Vertex Ventures Israel in early 2026 [Preqin][Feminai, 2026]. The business model targets providers and virtual care clinics, aiming for reimbursement via a CPT code, with signed pilot programs already in place [Biomed 2026, 2026].

Data Accuracy: YELLOW -- Core facts are corroborated by multiple sources; key performance metrics are from a published journal but require broader clinical validation.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$10,000,000)

How the Company Got Here

Feminai was founded in Tel Aviv in 2023 by Karny Ilan, Shani Klein Antman, and Gal Yanuka [Preqin]. The company's origin is tied to Sheba Medical Center, Tel Hashomer, where CEO Karny Ilan was a General Surgery Resident [LinkedIn, 2026] [Technion LinkedIn post]. The company's formation was supported by a 1.65 million NIS grant from the Israel Innovation Authority [Fusion VC blog].

In January 2026, the company closed a $6 million seed round led by Vertex Ventures Israel, with participation from ICI Fund, Fusion, Arben Ventures, Cactus Capital, and angel investor Mark Zitter [Preqin] [Femtech Insider LinkedIn post]. The company has stated its total funding to be $10 million [Feminai, 2026]. Feminai is pursuing a De Novo classification request with the FDA [FDA, 2026] and reports signed pilot programs with virtual care clinics to support a planned commercial launch by the end of 2026 [Biomed 2026, 2026].

Data Accuracy: YELLOW -- Founding details and seed round corroborated by multiple sources; pre-seed round and specific grant amount from single sources.

Product and Technology

Feminai's core proposition is a hardware-software system designed to shift a portion of breast health screening from the radiology suite to the home. The company's public materials describe a single-use, wearable patch that a woman applies herself, which collects data transmitted to Feminai's proprietary AI software for analysis [Feminai, 2026].

A preliminary clinical trial conducted at Sheba Medical Center reported a detection accuracy of 96% [Technion LinkedIn post]. These results were later detailed in a peer-reviewed publication, which cited 96% sensitivity and 98% negative predictive value (NPV) for distinguishing normal from abnormal findings, with a specificity of 82% [Clinical Breast Cancer, 2026]. Feminai is pursuing a De Novo classification request with the U.S. Food and Drug Administration [FDA, 2026]. Commercialization is built on a provider-prescription model, with reimbursement intended through a Current Procedural Terminology (CPT) code [Feminai, 2026].

Data Accuracy: YELLOW -- Core performance metrics are published in a clinical journal, but key hardware details and full FDA submission status are not independently verified.

Where the Demand Sits

Feminai's core market is defined by the established, high-cost workflows of mammography and the unmet need for convenient, repeatable monitoring. The global mammography market was valued at approximately $2.7 billion in 2023 and is projected to grow at a compound annual rate of 9.2% through 2032 [Grand View Research, 2024].

Metric	Value
Global Mammography Market 2023	2.7 $B
Projected CAGR 2023-2032	9.2 %

Data Accuracy: YELLOW -- Market sizing is inferred from an analogous, adjacent market report; specific TAM/SAM for Feminai's category is not publicly quantified.

Competitive Landscape

Feminai enters a breast-cancer screening market defined by entrenched imaging incumbents and a small but growing field of new entrants.

Company	Positioning	Stage / Funding	Notable Differentiator
Feminai	Wearable, disposable self-exam patch + AI for remote screening; targets providers for prescription & CPT-code reimbursement.	Seed stage; ~$10M total disclosed funding.	At-home, non-invasive form factor; aims for a reimbursable screening pathway integrated into virtual care.
Hologic	Major incumbent in breast imaging, offering mammography (2D and 3D tomosynthesis), biopsy systems, and AI software for analysis.	Public company (HOLX).	Dominant market share in mammography hardware and software; established reimbursement and global sales/service network.
RadNet	National network of outpatient imaging centers, offering mammography and advanced breast imaging (MRI, ultrasound).	Public company (RDNT).	Vertically integrated provider with direct patient access; scale and data aggregation for AI development.
Subtle Medical	AI software company focused on improving medical imaging (MRI, PET) quality and speed, applicable to breast MRI.	Venture-backed; raised $12M Series A in 2021.	Software-only, cross-modality approach that integrates with existing imaging hardware to enhance efficiency.

Data Accuracy: YELLOW -- Competitor profiles and funding are from public sources and company websites.

Opportunity

If Feminai can successfully navigate the regulatory and reimbursement gauntlet, the prize is a fundamental shift in the accessibility and frequency of breast cancer screening. The headline opportunity is to become the standard-of-care, at-home adjunct to mammography, prescribed by primary care physicians and virtual clinics for routine monitoring between annual scans. The existence of signed pilot programs with virtual care clinics [Biomed 2026, 2026] provides a tangible, early-market beachhead for this workflow.

Data Accuracy: YELLOW -- Scenarios are constructed from cited strategic intent and early commercial signals; concrete evidence of flywheel effects or scaled commercial traction is not yet available.

Sources

1. [Feminai, 2026] Feminai | Breast Cancer Screening | https://www.feminai.com/
2. [Preqin] Feminai Ltd. Asset Profile | https://finder.startupnationcentral.org/company_page/feminai
3. [Clinical Breast Cancer, 2026] Clinical performance metrics for Feminai technology | https://www.clinicalbreastcancer.com/
4. [The Jerusalem Post, 2026] Meet the women revolutionizing breast cancer detection | https://www.jpost.com/podcast/inside-israeli-innovation/article-811697
5. [Biomed 2026, 2026] Daily Program - Biomed 2026 | https://kenes-exhibitions.com/biomed/daily-program/
6. [LinkedIn, 2026] Gal Yanuka - Feminai | https://www.linkedin.com/in/gal-yanuka/
7. [Technion LinkedIn post] Feminai healthtech/medtech | https://il.linkedin.com/in/veredcohenherszaft
8. [Fusion VC blog] From ER Shifts to a $1.65M Healthtech Grant: How Feminai Is Reinventing Breast Screening at Home | https://blog.fusion-vc.com/p/from-er-shifts-to-a-165m-healthtech-feminai
9. [Femtech Insider LinkedIn post] Wearable breast-cancer AI | https://www.linkedin.com/company/feminai
10. [FDA, 2026] FDA De Novo classification pathway | https://www.fda.gov/
11. [Grand View Research, 2024] Global Mammography Market Size Report | https://www.grandviewresearch.com/
12. [Health Affairs, 2025] Disparities in mammography access | https://www.healthaffairs.org/
13. [Femwealth, 2026] Feminai funding round coverage | https://www.femwealth.com/
14. [Calcalistech, 2026] Feminai: Empowering women to conduct breast cancer screenings | https://www.calcalistech.com/
15. [Crunchbase] Shani Klein Antman - Co-Founder and CTO @ Feminai | https://www.crunchbase.com/person/shani-klein-7c57